High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer

Glioma tumor suppressor candidate region gene 1 (GLTSCR1) is associated with the progression of oligodendroglioma. However, there has been little study of GLTSCR1 in prostate cancer. In the present study, the association between the expression of GLTSCR1, and the progression and prognosis of tumors...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2018-11, Vol.16 (5), p.6749-6755
Main Authors: Ma, Xiaoming, Du, Tao, Zhu, Dingjun, Chen, Xianju, Lai, Yiming, Wu, Wanhua, Wang, Qiong, Lin, Chunhao, Li, Zean, Liu, Leyuan, Huang, Hai
Format: Article
Language:English
Subjects:
Age
Antigens
Brain cancer
Cancer therapies
Genomes
Glioma
Lymphatic system
Medical prognosis
Metastasis
Mortality
Multivariate analysis
Oncology
Prostate cancer
Radiation therapy
Studies
Survival analysis
Tumorigenesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioma tumor suppressor candidate region gene 1 (GLTSCR1) is associated with the progression of oligodendroglioma. However, there has been little study of GLTSCR1 in prostate cancer. In the present study, the association between the expression of GLTSCR1, and the progression and prognosis of tumors in patients with prostate cancer was assessed. An immunohistochemical analysis was performed using a human tissue microarray for GLTSCR1 at the protein expression level and the immunostaining results were evaluated against clinical variables of patients with prostate cancer. Subsequently, The Cancer Genome Atlas (TCGA) was used to validate the analysis results at the mRNA level and to study the prognostic value of GLTSCR1 in prostate cancer. Immunohistochemistry and TCGA data analysis revealed that GLTSCR1 expression in the prostate cancer tissues was significantly higher than that in the benign prostate tissues (immunoreactivity score, P=0.015; mRNA levels: cancer, 447.7±6.45 vs. benign, 343.5±4.21; P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2018.9490